Dupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2 Asthma by Allergen Sensitization Level.
Wanda Phipatanakul, Nikolaos G Papadopoulos, Vivian Hernandez-Trujillo et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of the multicenter, randomized VOYAGE trial examined dupilumab by allergen sensitization status in children aged 6 to 11 years with uncontrolled, moderate-to-severe type 2 asthma. Among 336 children with known sensitization status, dupilumab reduced severe asthma exacerbations by 45% in nonsensitized, 75% in monoallergen-sensitized, and 60% in multiallergen-sensitized subgroups by week 52. The treatment effect did not show an apparent interaction with sensitization status. Improvements in lung function, asthma control, and total IgE were also similar across subgroups.
Key findings
- Exacerbations were reduced by 45%, 75%, and 60% in nonsensitized, monoallergen-sensitized, and multiallergen-sensitized children, respectively.
- There was no apparent interaction between treatment group and sensitization status (P int = .48).
- Lung function, ACQ-7-IA scores, and total IgE improved similarly across sensitization subgroups.
- Exacerbation reductions were statistically significant in monoallergen- and multiallergen-sensitized groups, but not in the nonsensitized group.
Why it matters
The findings suggest that allergen sensitization status may not identify which children with type 2 asthma can benefit from dupilumab. The similar pattern across subgroups is clinically relevant because type 2 inflammation, rather than sensitization alone, defined the analyzed population. However, subgroup results should be interpreted in the context of the post hoc analysis.
What to keep in mind
This was a post hoc subgroup analysis of the randomized trial, and the nonsensitized subgroup was relatively small.